Sunshine Receivables Turnover from 2010 to 2024

SBFMW Stock  USD 0.17  0.04  19.05%   
Sunshine Biopharma Receivables Turnover yearly trend continues to be fairly stable with very little volatility. Receivables Turnover will likely drop to 8.97 in 2024. During the period from 2010 to 2024, Sunshine Biopharma Receivables Turnover regression line of quarterly data had mean square error of  452.38 and geometric mean of  5.03. View All Fundamentals
 
Receivables Turnover  
First Reported
2010-12-31
Previous Quarter
9.43940828
Current Value
8.97
Quarterly Volatility
21.68350856
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 30.3 M or Total Operating Expenses of 13.8 M, as well as many indicators such as Price To Sales Ratio of 0.26, Dividend Yield of 0.0 or PTB Ratio of 0.3. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Receivables Turnover Growth Pattern

Below is the plot of the Receivables Turnover of Sunshine Biopharma Warrant over the last few years. It is Sunshine Biopharma's Receivables Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
Receivables Turnover10 Years Trend
Slightly volatile
   Receivables Turnover   
       Timeline  

Sunshine Receivables Turnover Regression Statistics

Arithmetic Mean19.13
Geometric Mean5.03
Coefficient Of Variation113.32
Mean Deviation19.76
Median8.97
Standard Deviation21.68
Sample Variance470.17
Range48.5696
R-Value0.33
Mean Square Error452.38
R-Squared0.11
Significance0.24
Slope1.58
Total Sum of Squares6,582

Sunshine Receivables Turnover History

2024 8.97
2023 9.44
2022 2.27
2021 29.29
2020 37.27
2016 49.12

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Receivables Turnover, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Receivables Turnover 9.44  8.97 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.